公开(公告)号：US20140335132A1

公开(公告)日：2014-11-13

申请号：US13885503

申请日：2011-11-22

申请人： Helen Mary Burt ,  John Kevin Jackson ,  Wadood Yasser Hamad

发明人： Helen Mary Burt ,  John Kevin Jackson ,  Wadood Yasser Hamad

IPC分类号： A61K47/48 ,  A61K31/65 ,  A61K45/06 ,  A61K31/704

CPC分类号： A61K31/65 ,  A61K9/2054 ,  A61K31/704 ,  A61K45/06 ,  A61K47/61

摘要： This invention describes nanocrystalline cellulose (NCC) for use as a drug delivery excipient. NCC binds significant quantities of water soluble, ionizable drugs, e.g., tetratcycline and doxorubicin, which are released rapidly over a one day period. A surfactant such as cetyl trimethylammonium bromide (CTAB) can bind to the surface of NCC and increase the zeta potential in a concentration-dependent manner from −55 to 0 mV. NCC with CTAB modified surfaces can bind significant quantities of the hydrophobic drugs such as anticancer drugs docetaxel, paclitaxel and etoposide. These drugs were released in a controlled manner over a 2-day period. The NCC-CTAB nanocomplexes were found to bind to KU-7 cells and evidence of cellular uptake was observed.

摘要翻译： 本发明描述了用作药物递送赋形剂的纳米晶体纤维素（NCC）。 NCC结合大量的水溶性可电离药物，例如四环素和多柔比星，它们在一天内快速释放。 表面活性剂如十六烷基三甲基溴化铵（CTAB）可以结合NCC的表面，并以浓度依赖的方式将ζ电位从-55增加到0mV。 具有CTAB改性表面的NCC可以结合大量的疏水药物，例如抗癌药物多西紫杉醇，紫杉醇和依托泊苷。 这些药物在2天的时间内以受控的方式释放。 发现NCC-CTAB纳米复合物与KU-7细胞结合，观察到细胞摄取的证据。